drugset
drugset / Trial / NCT04914117

A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

NCT04914117 ↗

Phase 1 Completed 7 enrolled RemeGen Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients with Locally Advanced Unresectable/Metastatic Solid Tumours to determine the safety and tolerability of RC118, including the maximum tolerated dose (MTD)/maximum administered dose (MAD), and to define the recommended Phase II dose (RP2D).

Timeline

Start
2021-11-29
Primary completion
2022-11-15
Completion
2023-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject RC118 Unknown 0.25 mg/kg Intravenous
Subject RC118 Unknown 0.5 mg/kg Intravenous
Subject RC118 Unknown 1 mg/kg Intravenous
Subject RC118 Unknown 1.5 mg/kg Intravenous
Subject RC118 Unknown 2 mg/kg Intravenous
Subject RC118 Unknown 2.5 mg/kg Intravenous
Subject RC118 Unknown 3 mg/kg Intravenous

Indications

metastatic neoplasm